Technical Data
C2275-83A
CD25 (Tac antigen, p55, Interleukin 2 Receptor alpha, IL2Ra, T Cell Growth Factor Receptor)
Description:
Expression of human CD25 (the alpha subunit of the IL-2 receptor complex) is dramatically upregulated on activated T cells, B cells, NK cells and macrophages (3). Antibodies to CD25 are being studied for potential use as an immundirected therapy to selectively attack (kill) CD25 expressing cells (4).

Applications:
Suitable for use in Flow Cytometry, Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: Frozen sections
Flow Cytometry: 5ug/ml
Optimal dilutions to be determined by the researcher.

Flow Cytometry Protocol:
1. Cultured human CEM were stimulated overnight in the presence of PMA (10ng/ml) and ionomycin (1uM).
2. Five x 10e5 cells per tube were washed and incubated 45 minutes on ice with 80ul of aC2275-83A at 5ug/ml.
3. Cells were washed twice and incubated with secondary reagent Goat anti-Mouse IgG/FITC after which they were washed three times, fixed and analyzed by FACS.
4. Cells stained positive with a mean shift of 1.36 log10 fluorescent units when compared to a Mouse IgG2a negative control at a similar concentration.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2a,k7H136Affinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Stimulated PBMC
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.2, 0.5mg/ml gentamicin sulfate.
Specificity:
Recognizes epitope B of the human IL-2 alpha receptor of about 55kD. Does not block IL-2 binding to its receptor.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. L.A. Rubin, et al, (1985) Hybidoma 4: 91-102. 2) B. Boutin, et al, (1989) Neuropediatrics 20: 202-206.3) T.A. Waldmann, et al, (1989) Annu Rev Biochem 58: 875-911. (4) T.A. Waldmann, et al, (1995) Blood 86: 4063-4075. (5) U.S. Patent No. 4,707,443. (6) Leukocyte Typing IV (W. Knapp, et al, eds.) Oxford University Press, Oxford, (1989) p. 403-406